Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Research & Development, LLC
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
Were first diagnosed with depression before the age of 55
Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
Have taken 0, 1, or 2 treatments for depression in your current episode
Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m\^2) at screening
You may not be if
Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
Post-traumatic stress disorder within the past three years of screening
Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
Clareo Health | A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
